TSE:TRL

Trilogy International Partners Competitors

C$1.77
-0.02 (-1.12 %)
(As of 07/30/2021 11:40 AM ET)
Add
Compare
Today's Range
C$1.77
C$1.80
50-Day Range
C$1.77
C$2.00
52-Week Range
C$0.85
C$2.11
Volume8,210 shs
Average Volume30,833 shs
Market CapitalizationC$106.06 million
P/E RatioN/A
Dividend Yield1.43%
BetaN/A

Trilogy International Partners (TSE:TRL) Vs. TH, BU, CRH, VMD, SVA, and PLI

Should you be buying TRL stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Trilogy International Partners, including Theratechnologies (TH), Burcon NutraScience (BU), CRH Medical (CRH), Viemed Healthcare (VMD), Sernova (SVA), and ProMetic Life Sciences (PLI).

Theratechnologies (TSE:TH) and Trilogy International Partners (TSE:TRL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Theratechnologies and Trilogy International Partners' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.39 million6.11C$-35,319,540.00C($0.37)-11.48
Trilogy International PartnersC$626.85 million0.17C$-59,441,632.00C($0.99)-1.78

Theratechnologies has higher earnings, but lower revenue than Trilogy International Partners. Theratechnologies is trading at a lower price-to-earnings ratio than Trilogy International Partners, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Trilogy International Partners' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Trilogy International PartnersN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Theratechnologies and Trilogy International Partners, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Trilogy International Partners00103.00

Theratechnologies presently has a consensus price target of C$3.75, suggesting a potential downside of 12.18%. Trilogy International Partners has a consensus price target of C$3.33, suggesting a potential upside of 88.32%. Given Trilogy International Partners' stronger consensus rating and higher possible upside, analysts plainly believe Trilogy International Partners is more favorable than Theratechnologies.

Summary

Trilogy International Partners beats Theratechnologies on 5 of the 8 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Trilogy International Partners (TSE:TRL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Burcon NutraScience and Trilogy International Partners' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$258,646.001,446.33C$-650,586.00C($0.01)-575.00
Trilogy International PartnersC$626.85 million0.17C$-59,441,632.00C($0.99)-1.78

Burcon NutraScience has higher earnings, but lower revenue than Trilogy International Partners. Burcon NutraScience is trading at a lower price-to-earnings ratio than Trilogy International Partners, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Burcon NutraScience and Trilogy International Partners' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
Trilogy International PartnersN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Burcon NutraScience and Trilogy International Partners, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
Trilogy International Partners00103.00

Burcon NutraScience currently has a consensus target price of C$5.00, suggesting a potential upside of 44.93%. Trilogy International Partners has a consensus target price of C$3.33, suggesting a potential upside of 88.32%. Given Trilogy International Partners' higher probable upside, analysts plainly believe Trilogy International Partners is more favorable than Burcon NutraScience.

CRH Medical (TSE:CRH) and Trilogy International Partners (TSE:TRL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Profitability

This table compares CRH Medical and Trilogy International Partners' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRH MedicalN/AN/AN/A
Trilogy International PartnersN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for CRH Medical and Trilogy International Partners, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRH Medical02002.00
Trilogy International Partners00103.00

CRH Medical presently has a consensus target price of C$5.05, suggesting a potential upside of 1.20%. Trilogy International Partners has a consensus target price of C$3.33, suggesting a potential upside of 88.32%. Given Trilogy International Partners' stronger consensus rating and higher possible upside, analysts clearly believe Trilogy International Partners is more favorable than CRH Medical.

Earnings & Valuation

This table compares CRH Medical and Trilogy International Partners' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRH MedicalC$106.17 million3.37C$-29,865,540.00C($0.42)-11.97
Trilogy International PartnersC$626.85 million0.17C$-59,441,632.00C($0.99)-1.78

CRH Medical has higher earnings, but lower revenue than Trilogy International Partners. CRH Medical is trading at a lower price-to-earnings ratio than Trilogy International Partners, indicating that it is currently the more affordable of the two stocks.

Summary

Trilogy International Partners beats CRH Medical on 5 of the 8 factors compared between the two stocks.

Trilogy International Partners (TSE:TRL) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Trilogy International Partners and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trilogy International PartnersN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Earnings and Valuation

This table compares Trilogy International Partners and Viemed Healthcare's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trilogy International PartnersC$626.85 million0.17C$-59,441,632.00C($0.99)-1.78
Viemed HealthcareC$135.92 million2.53C$35.22 millionC$0.899.75

Viemed Healthcare has lower revenue, but higher earnings than Trilogy International Partners. Trilogy International Partners is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trilogy International Partners and Viemed Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trilogy International Partners00103.00
Viemed Healthcare01002.00

Trilogy International Partners presently has a consensus price target of C$3.33, suggesting a potential upside of 88.32%. Given Trilogy International Partners' stronger consensus rating and higher possible upside, research analysts clearly believe Trilogy International Partners is more favorable than Viemed Healthcare.

Trilogy International Partners (TSE:TRL) and Sernova (CVE:SVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Trilogy International Partners and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trilogy International PartnersN/AN/AN/A
SernovaN/AN/AN/A

Earnings & Valuation

This table compares Trilogy International Partners and Sernova's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trilogy International PartnersC$626.85 million0.17C$-59,441,632.00C($0.99)-1.78
SernovaN/AN/AN/AC($0.03)-49.62

Sernova has lower revenue, but higher earnings than Trilogy International Partners. Sernova is trading at a lower price-to-earnings ratio than Trilogy International Partners, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Trilogy International Partners and Sernova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trilogy International Partners00103.00
Sernova0000N/A

Trilogy International Partners currently has a consensus price target of C$3.33, suggesting a potential upside of 88.32%. Given Trilogy International Partners' higher possible upside, analysts plainly believe Trilogy International Partners is more favorable than Sernova.

Summary

Trilogy International Partners beats Sernova on 4 of the 5 factors compared between the two stocks.

ProMetic Life Sciences (TSE:PLI) and Trilogy International Partners (TSE:TRL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ProMetic Life Sciences and Trilogy International Partners, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Trilogy International Partners00103.00

Trilogy International Partners has a consensus target price of C$3.33, suggesting a potential upside of 88.32%.

Profitability

This table compares ProMetic Life Sciences and Trilogy International Partners' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
Trilogy International PartnersN/AN/AN/A

Earnings and Valuation

This table compares ProMetic Life Sciences and Trilogy International Partners' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
Trilogy International PartnersC$626.85 million0.17C$-59,441,632.00C($0.99)-1.78

Trilogy International Partners has higher revenue and earnings than ProMetic Life Sciences. Trilogy International Partners is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Trilogy International Partners beats ProMetic Life Sciences on 4 of the 5 factors compared between the two stocks.


Trilogy International Partners Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Theratechnologies logo
TH
Theratechnologies
1.1$4.27-3.5%C$405.42 millionC$66.39 million-11.48Positive News
BU
Burcon NutraScience
1.6$3.45-2.9%C$374.09 millionC$258,646.00-575.00
CRH Medical logo
CRH
CRH Medical
1.1$4.99-0.4%C$357.38 millionC$106.17 million-11.97
VMD
Viemed Healthcare
0.3$8.68-0.1%C$343.53 millionC$135.92 million9.75
SVA
Sernova
0.8$1.29-0.8%C$334.39 millionN/A-49.62Upcoming Earnings
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.9N/AN/AC$317.06 millionC$39.91 million-0.22
APS
Aptose Biosciences
1.8$3.37-3.0%C$299.74 millionN/A-3.80Upcoming Earnings
Hamilton Thorne logo
HTL
Hamilton Thorne
1.4$2.06-0.5%C$290.30 millionC$40.90 million137.33Positive News
Gap Down
AKU
Akumin
1.3$3.96-2.0%C$281.77 millionC$241.84 million-10.05Gap Up
BLU
BELLUS Health
0.9$3.55-2.8%C$278.10 millionC$15,000.00-4.89
RIV
RIV Capital
1.6$1.88-1.1%C$267.78 millionC$13.43 million-2.61Gap Up
Medical Facilities logo
DR
Medical Facilities
1.7$8.25-1.6%C$256.62 millionC$365.09 million55.37
ABCN
VIVO Cannabis
1.0$1.32-5.3%C$256.62 millionN/A0.00News Coverage
Gap Up
FIRE
The Supreme Cannabis
1.3$0.34-1.5%C$255.58 millionC$53.29 million-10.81News Coverage
EMC
Emblem
0.9$1.88-1.6%$245.45 million$5.71 million-9.89
EPI
ESSA Pharma
1.0$8.20-6.7%C$237.87 millionN/A-8.27
KSI
kneat.com
1.6$3.08-1.3%C$235.65 millionC$8.82 million-22.48
TMD
Titan Medical
1.0$2.11-2.8%C$231.10 millionC$20.05 million-3.56
Leaf Mobile logo
LEAF
Leaf Mobile
1.8$0.30-0.0%C$229.40 millionC$78.08 million12.50Gap Up
ICC
ICC Labs
0.9$1.62-6.2%C$223.64 millionC$533,684.0095.29Gap Up
FRX
Fennec Pharmaceuticals
0.9$8.17-1.0%C$212.45 millionC$170,000.00-8.65Upcoming Earnings
News Coverage
VMD
Viemed Healthcare
0.9$4.95-2.0%C$187.65 millionN/A0.00Gap Down
IMV logo
IMV
IMV
1.6$2.22-2.7%C$182.22 millionC$2,385.00-4.17Gap Up
IPA
ImmunoPrecise Antibodies
0.7$8.22-2.3%C$182.12 millionC$17.91 million-18.43Gap Down
IVQ
Invesque
1.0$3.24-2.8%C$181.68 millionC$213.61 million-1.16News Coverage
Gap Up
Antibe Therapeutics logo
ATE
Antibe Therapeutics
2.0$3.39-0.9%C$174.18 millionC$9.71 million-4.80
NEPT
Neptune Wellness Solutions
1.4$1.01-1.0%C$168.75 millionC$46.81 million-0.73Positive News
Gap Down
The Green Organic Dutchman logo
TGOD
The Green Organic Dutchman
1.4$0.32-0.0%C$168.70 millionC$26.27 million-1.39
MDNA
Medicenna Therapeutics
0.9$3.15-1.9%C$168.69 millionN/A-9.05Upcoming Earnings
RVX
Resverlogix
1.0$0.67-0.0%C$159.97 millionN/A47.86
ONC
Oncolytics Biotech
2.0$2.89-1.7%C$157.99 millionN/A-4.31Upcoming Earnings
News Coverage
MDP
Medexus Pharmaceuticals
1.8$7.75-5.2%C$148.54 millionC$108.29 million-4.28
DMT
Small Pharma
0.0$0.46-0.0%C$145.73 millionC$45,000.00-4.11Positive News
Gap Up
IOM
Assure
0.9$2.24-8.9%C$126.80 millionC$3.96 million-4.69Gap Down
CRDL
Cardiol Therapeutics
1.5$2.83-6.4%C$120.85 millionN/A-3.41
ACST
Acasti Pharma
0.9$0.57-0.0%C$118.77 millionC$196,000.00-2.75
HBP
Helix BioPharma
0.9$0.83-6.0%C$117.14 millionN/A-15.37Gap Down
MediPharm Labs logo
LABS
MediPharm Labs
1.9$0.43-2.3%C$110.92 millionC$30.42 million-1.05
WLLW
Willow Biosciences
1.7$0.88-1.1%C$108.65 millionC$14,000.00-1.80
SCYB
Scythian Biosciences
0.9$3.49-6.3%C$102.38 millionN/A0.00High Trading Volume
COM
138267 (COM.TO)
0.9$2.95-2.7%C$102.19 millionN/A0.00
EDT
Spectral Medical
0.9$0.38-0.0%C$101.72 millionC$2.22 million-12.26News Coverage
NVH
Novoheart
0.9$0.53-1.9%C$99.98 millionC$423,500.00-13.95
BioSyent logo
RX
BioSyent
1.2$7.75-1.3%C$98.29 millionC$23.69 million25.16
BCT
BriaCell Therapeutics
1.2$6.42-7.5%C$97.65 millionN/A5.28Gap Down
NINE
Delta 9 Cannabis
1.4$1.03-2.9%C$89.36 millionC$12.87 million19.07Gap Up
IGX
IntelGenx Technologies
0.9$0.55-3.6%C$82.11 millionC$1.63 million-7.05Gap Up
MBX
Microbix Biosystems
1.3$0.61-3.3%C$74.26 millionC$13.12 million-14.88
The Flowr logo
FLWR
The Flowr
1.4$0.18-2.8%C$71.67 millionC$10.57 million-0.27
PMN
ProMIS Neurosciences
0.9$0.20-7.7%C$68.44 millionC$1,787.00-4.88Gap Down
This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.